A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients-Reference-Cited by-同舟云学术

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

Published:2019-07-31 Issue:5 Volume:121 Page:378-383
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Elez Elena,Pericay Carles,Valladares-Ayerbes Manuel,Bando Inmaculada,Safont Maria Jose,Gallego Javier,Grávalos Cristina,Arrivi Antonio,Carrato Alfredo,Conde Verónica,Ortiz Maria José,López Carlos,Alonso Beatriz,Ruiz de Mena Inmaculada,Díaz-Rubio Eduardo,Tabernero Josep,Aranda Enrique

Funder

Amgen S.A.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-019-0537-z.pdf

Reference27 articles.

1. Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H. Aderka, D. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386–1422 (2016).

2. Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A. Lutz, M. P. et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 2311–2319 (2008).

3. Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M. Hotko, Y. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 4706–4713 (2010).

4. Seymour, M. T., Brown, S. R., Middleton, G., Maughan, T., Richman, S. Gwyther, S. et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 14, 749–759 (2013).

5. Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O’Callaghan, C. J., Tu, D. Tebbutt, N. C. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008).

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A roadmap for medical treatment of metastatic CRC;Foundations of Colorectal Cancer;2022

2. The Alpha-Lipoic Acid Improves Survival and Prevents Irinotecan-Induced Inflammation and Intestinal Dysmotility in Mice;Pharmaceuticals;2020-11-03